|
|
 Home  Xml
Feed  Submit Articles  Editor Login  Contact us |
 |
 |
|
|
Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020) With sales worth US$ 57 Million in 2010, biosimilars are still far from their billion dollar sales potential that most analysts believe they will generate. This market, however, unlike small molecule generics, is expected to be more akin to a marathon than a sprint. http://www.bharatbook.com/detail.asp?id=214718&rt=Biosimilar-Follow-on-Biologics-Market-Report-Forecast-A-Focus-on-the-US-2011-2020.html A Focus on the US (2011-2020)” finds that biosimilars in the US will soon represent a multi-billion dollar market as they would be posing stiff competition to as many as twenty biological molecules during 2011-2020. Findings from the report suggest that the historical performance of Omnitrope cannot be taken as a benchmark to gauge the potential of pipeline biosimilars as market acceptance for each biosimilar class is expected to vary significantly from one another. The report expects that the competition between branded biological drugs and their biosimilar counterparts would be more of a brand-brand competition than a brand-generic competition. The high costs involved in the development and launch of biosimilars are expected to limit the number of players in this market. As a result, erosions in price and volume caused by biosimilars are likely to be lower compared to those created by small molecule generics. New report entitled “Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)” provides an analytical and statistical insight into the US biosimilar market. The study, that has been undertaken using desk-based as well as qualitative primary research, provides and draws upon analysis of six aspects of the US biosimilar market. Key Aspects Analyzed: Evaluating the Current Market Landscape of Biosimilars: • Identification of currently marketed biosimilars and their historical performance • Identifying the reasons for the slow uptake of currently marketed biosimilars • Analyzing historical data to formulate conclusions on the future growth and market trends of biosimilars Evaluating the Extent of Price, Sales and Volume Erosions Caused by Biosimilars: • Analyzing historical time series data on price, volume and sales erosion in the US & Europe • Analyzing previous models and assumptions on price and volume erosion caused by biosimilars • Evaluating and comparing price and volume erosion created by biosimilars vis-a-vis by small molecule generics • Evaluating and comparing price, volume and sales erosion by biosimilars across various biological classes For more information kindly visit : Biosimilar and Follow-On-Biologics Development in US through Bharatbook.com Or Contact us at : Bharat Book Bureau Tel: +91 22 27578668/+91 22 27579438 Fax: +91 22 27579131 Email: info@bharatbook.com Website: www.bharatbook.com Follow us on twitter: http://twitter.com/#!/Sandhya3B
About the Author:
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Biosimilar and Follow-On-Biologics Development in US through Bharatbook.com
